Dose escalation based on 18F-FDG PET/CT response in definitive chemoradiotherapy of locally advanced esophageal squamous cell carcinoma: a phase III, open-label, randomized, controlled trial (ESO-Shang…

Overview of attention for article published in Radiation Oncology, July 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 19 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 1 X post from an account with 543 followers.

Is dose escalation or de-escalation research of EC coming to the end? Along with the British SCOPE 2 study, our ongoing ESO-Shanghai 12 phase III trial aims to precise the PET-based dose escalation in dCRT and tailor therapy for EC patients. @BioMedCentral

30 Jul 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.